Request Appointment
530 East 74th StreetNew York, NY 10021
Overview of Dr. Awad
Dr. Mark Awad is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital, and Dana-Farber Cancer Institute. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 9 years. He is one of 361 doctors at Brigham and Women's Hospital and one of 452 doctors at Dana-Farber Cancer Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
Johns Hopkins University School of MedicineClass of 2008
Certifications & Licensure
FL State Medical License 2024 - Present
NY State Medical License 2024 - 2026
MA State Medical License 2012 - 2025
NJ State Medical License 2024 - 2025
NH State Medical License 2024 - 2024
RI State Medical License 2020 - 2020
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Merestinib In Non-Small Cell Lung Cancer And Solid Tumors Start of enrollment: 2016 Nov 11
- A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma Start of enrollment: 2017 Apr 10
- A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Start of enrollment: 2017 Jun 19
- Join now to see all
Publications & Presentations
PubMed
- Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.Mark M Awad, Patrick M Forde, Nicolas Girard, Jonathan Spicer, Changli Wang
Journal of Clinical Oncology. 2025-04-20 - Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell ...Federica Pecci, Rohit Thummalapalli, Stephanie L Alden, Biagio Ricciuti, Joao V Alessi
Clinical Cancer Research. 2025-04-18 - Antitumor activity of vebreltinib and characterization of clinicogenomic features in solid tumors with MET rearrangements.Seshiru Nakazawa, Federica Pecci, Igor Odintsov, Dimitris Gazgalis, Felix H Gottlieb
Cancer Discovery. 2025-04-10
Journal Articles
- Authors’ ResponseMatthew P Cheng, Mark M Awad, Journal of Thoracic Oncology
Lectures
- Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC).2019 ASCO Annual Meeting - 6/1/2019
- Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non small cel...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Authors’ ResponseOctober 2018
Press Mentions
Lung Cancer Remains at Bay Long After Immune Therapy Is DroppedApril 21st, 2025- Immunotherapy Effects Persist Post-Treatment: StudyApril 19th, 2025
- Encouraging Results After Discontinuation of Cancer Immunotherapy Due to Immune AEsApril 18th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
